BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20863968)

  • 1. [Infliximab treatment for chronic sarcoidosis--a case series].
    Jounieaux F; Chapelon C; Valeyre D; Israel Biet D; Cottin V; Tazi A; Fournier E; Wallaert B;
    Rev Mal Respir; 2010 Sep; 27(7):685-92. PubMed ID: 20863968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.
    Fautrel B; Sibilia J; Mariette X; Combe B;
    Ann Rheum Dis; 2005 Feb; 64(2):262-6. PubMed ID: 15184196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial.
    Judson MA; Baughman RP; Costabel U; Mack M; Barnathan ES
    Respir Med; 2014 Jan; 108(1):189-94. PubMed ID: 24361164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of infliximab in treating selected patients with sarcoidosis.
    Saleh S; Ghodsian S; Yakimova V; Henderson J; Sharma OP
    Respir Med; 2006 Nov; 100(11):2053-9. PubMed ID: 16935484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Successful treatment with infliximab of a patient with refractory sarcoidosis].
    Fouchier SM; Möller GM; Van Santen-Hoeufft M; Faber CG; Smeenk FW; Drent M
    Ned Tijdschr Geneeskd; 2004 Dec; 148(49):2446-50. PubMed ID: 15626311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab.
    Garrity JA; Coleman AW; Matteson EL; Eggenberger ER; Waitzman DM
    Am J Ophthalmol; 2004 Dec; 138(6):925-30. PubMed ID: 15629282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab for treating sarcoidosis patients, Portuguese experience.
    Aguiar M; Marçal N; Mendes AC; Bugalho de Almeida A
    Rev Port Pneumol; 2011; 17(2):85-93. PubMed ID: 21477572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.
    Baughman RP; Drent M; Kavuru M; Judson MA; Costabel U; du Bois R; Albera C; Brutsche M; Davis G; Donohue JF; Müller-Quernheim J; Schlenker-Herceg R; Flavin S; Lo KH; Oemar B; Barnathan ES;
    Am J Respir Crit Care Med; 2006 Oct; 174(7):795-802. PubMed ID: 16840744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.
    Kalb RE; Gurske J
    J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
    Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D
    Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab treatment for steroid-refractory acute graft-versus-host disease.
    Patriarca F; Sperotto A; Damiani D; Morreale G; Bonifazi F; Olivieri A; Ciceri F; Milone G; Cesaro S; Bandini G; Dini G; Corradini P; Fanin R
    Haematologica; 2004 Nov; 89(11):1352-9. PubMed ID: 15531458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
    Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with infliximab in patients with sarcoidosis.
    Hostettler KE; Studler U; Tamm M; Brutsche MH
    Respiration; 2012; 83(3):218-24. PubMed ID: 21811048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effect of infliximab on refractory sarcoidosis.
    Ørum M; Hilberg O; Krag S; Bendstrup E
    Dan Med J; 2012 Dec; 59(12):A4535. PubMed ID: 23290282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
    Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G
    Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
    Su C; Salzberg BA; Lewis JD; Deren JJ; Kornbluth A; Katzka DA; Stein RB; Adler DR; Lichtenstein GR
    Am J Gastroenterol; 2002 Oct; 97(10):2577-84. PubMed ID: 12385442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.